LivaNova (NASDAQ:LIVN) Releases Quarterly Earnings Results

LivaNova (NASDAQ:LIVN) issued its quarterly earnings results on Wednesday. The company reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $1.06 by $0.17, FiscalAI reports. The company had revenue of $393.15 million for the quarter, compared to analyst estimates of $381.13 million. LivaNova had a return on equity of 16.10% and a net margin of 13.01%. The company’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period in the previous year, the company posted $1.11 earnings per share.

Here are the key takeaways from LivaNova’s conference call:

• Broad-based growth led to higher guidance. Third-quarter revenue rose 10% to $393 million, and LivaNova raised its 2026 revenue growth outlook to 9%–10% and adjusted EPS outlook to $4.40–$4.50.
• Cardiopulmonary growth and capacity expansion are supporting further gains. Segment revenue increased 11%, with strength in heart-lung machines and consumables; a new oxygenator line is operational, and the company expects double-digit output growth in 2027.
• Epilepsy momentum strengthened. Revenue grew 11%, supported by higher volume and realized pricing, clinical evidence, and improved reimbursement; LivaNova raised its 2026 epilepsy growth outlook to 8%–9%.
• OSA remains a key future growth opportunity, though commercialization is still ahead. The company cited differentiated clinical results and new category CPT codes expected to take effect in 2028, while planning a limited launch in 2027 and larger commercial investment beginning in 2028.
• Investment and working-capital needs weighed on cash generation. Quarterly adjusted free cash flow fell to $56 million from $62 million a year earlier, while capital spending increased; full-year adjusted free cash flow guidance was maintained at $140 million–$160 million.

LivaNova Stock Down 1.3%

LIVN traded down $1.15 on Friday, hitting $89.99. 443,949 shares of the company were exchanged, compared to its average volume of 746,132. LivaNova has a 12 month low of $49.73 and a 12 month high of $99.38. The company has a market cap of $4.96 billion, a PE ratio of 30.00 and a beta of 0.91. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.46. The stock’s fifty day moving average is $79.08 and its 200-day moving average is $73.40.

Insider Activity at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 3,500 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $78.01, for a total value of $273,035.00. Following the completion of the transaction, the director directly owned 4,434 shares in the company, valued at $345,896.34. This trade represents a 44.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Brooke Story sold 2,300 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $81.42, for a total value of $187,266.00. Following the transaction, the director directly owned 7,488 shares in the company, valued at $609,672.96. This trade represents a 23.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 7,450 shares of company stock valued at $591,839 over the last three months. Insiders own 0.35% of the company’s stock.

Wall Street Analyst Weigh In

LIVN has been the topic of a number of recent research reports. Stifel Nicolaus set a $85.00 target price on LivaNova in a research report on Wednesday, August 5th. Barclays raised LivaNova to a “strong-buy” rating in a research report on Wednesday, October 7th. Raymond James Financial set a $120.00 price target on shares of LivaNova in a research note on Wednesday. Mizuho set a $115.00 price objective on shares of LivaNova in a report on Wednesday. Finally, Zacks Research lowered shares of LivaNova from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $99.56.

About LivaNova

LivaNova PLC (NASDAQ: LIVN) is a medical technology company that develops and manufactures devices and therapies for patients with neurological and cardiovascular conditions. Its products are used by hospitals, physicians and other healthcare providers in markets around the world.

The company’s Neuromodulation business is best known for VNS Therapy, which uses an implanted device to deliver electrical stimulation to the vagus nerve. The therapy is used primarily for drug-resistant epilepsy and treatment-resistant depression, subject to applicable regulatory approvals.